Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:08 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 230 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: N Acetyl Cysteine Clear all

Conditions: Pruritus, Skin Disorder
Interventions: N-acetyl cysteine, Placebo; Drug
Lead sponsor: Wright State University; Other
Eligibility: 18 Years to 40 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Fairborn, Ohio

Conditions: Early Memory Loss, Mild Cognitive Impairment, Alzheimer's Disease, Vascular Dementia
Interventions: CerefolinNAC®; Other
Lead sponsor: Pamlab, Inc.; Industry
Eligibility: 50 Years to 80 Years
Enrollment: 204 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Hickory, North Carolina

Conditions: Schizophrenia, Cognitive Deficits, Schizophrenia; Negative Type
Interventions: N-acetylcysteine, Treatment as Usual; Drug · Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 65 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Cannabis Dependence
Interventions: N-Acetylcysteine; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 12 Years to 20 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Asthma
Interventions: n-acetylcystine, 0.9% saline; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 70 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Hangover Symptoms, NAC
Interventions: N Acetyl Cysteine, placebo; Dietary Supplement · Other
Lead sponsor: St. Luke's Hospital and Health Network, Pennsylvania; Other
Eligibility: 21 Years and older
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Bethlehem, Pennsylvania

Conditions: Parkinson Disease, Idiopathic Parkinson Disease
Interventions: Intravenous and Oral n-acetyl cysteine, Control group, Oral Supplements: Baicalin, Ganoderma, Omega 3 and Curcumin; Dietary Supplement · Other
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 30 Years to 80 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: N-acetyl cysteine, Placebo; Drug
Lead sponsor: Fernando J Martinez; Other
Eligibility: 40 Years and older
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 25
States / cities: Tucson, Arizona • Los Angeles, California • Stanford, California + 22 more

Conditions: Nephropathy
Interventions: intravenous NAC, Placebo; Drug
Lead sponsor: Ochsner Health System; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Retinitis Pigmentosa (RP), Usher Syndrome
Interventions: Placebo, NPI-001; Drug
Lead sponsor: Nacuity Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Healthy
Interventions: Delta-9-THC, N-acetylcysteine, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: NAFLD
Interventions: AXA1957, AXA1125, Placebo; Dietary Supplement
Lead sponsor: Axcella Health, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 18
States / cities: Chandler, Arizona • Tucson, Arizona • Huntington Park, California + 14 more

Conditions: Liver Failure, Liver Failure, Acute, Drug Induced Liver Injury, Prevention & Control, Fever
Interventions: APAP and NAC combination, APAP and Placebo; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Pediatric Traumatic Brain Injury
Interventions: Probenecid and N-acetyl cysteine, Placebo; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 2 Years to 18 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Neurofibromatosis 1
Interventions: N-Acetyl cysteine, Placebo; Drug · Other
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 8 Years to 16 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Acetaminophen, Drug Overdose, Acetaminophen Overdose, Acetaminophen Poisoning, Drug-induced Liver Injury, Liver Failure, Liver Toxicity
Interventions: Intravenous infusion of N-acetylcysteine, Intravenous infusion of Fomepizole (4-MP); Drug
Lead sponsor: Richard Dart, MD, PhD; Other
Eligibility: 10 Years to 99 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Bipolar Disorder, Depression
Interventions: N-acetyl cysteine (NAC); Drug
Lead sponsor: Martin Lan; Other
Eligibility: 18 Years to 60 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Pilon Fracture
Interventions: N-acetylcysteine, Saline; Drug
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Hemodialysis Catheter-related Bacteremia
Interventions: tigecycline, N-acetylcysteine, heparin combination, guide-wire exchange; Drug · Device
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 100 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 1
States / cities: San Diego, California

Conditions: Cornelia de Lange Syndrome
Interventions: N-acetyl cysteine, Placebo; Drug · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 13 Years to 35 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Bone Marrow Suppression, Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ, Long-term Effects Secondary to Cancer Therapy in Children
Interventions: filgrastim, acetylcysteine, carboplatin, cyclophosphamide, etoposide phosphate, mannitol, sodium thiosulfate; Biological · Drug
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 1 Year to 18 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Neuropathic Pain
Interventions: N-acetyl-l-cysteine; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Marijuana Abuse
Interventions: N-acetyl cysteine; Drug
Lead sponsor: Wayne State University; Other
Eligibility: 21 Years to 55 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Alcoholism
Interventions: N-acetylcysteine + high-dose naltrexone (150 mg), High-dose naltrexone (150 mg) alone, Low-dose naltrexone (50 mg) alone; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 2
States / cities: West Haven, Connecticut • Minneapolis, Minnesota

Search by objective public record fields.

Defining N-Acetyl Cysteine as a Treatment for Inhibiting Prurogenic Stimuli

NAC-003 P.L.U.S. Program (Progress Through Learning Understanding & Support)

Treatment of Cognitive and Negative Symptoms in Schizophrenia With N-acetylcysteine

An Open-Label Trial of N-Acetylcysteine in Cannabis Dependent Adolescents

Clinical Trial of NAC in Asthma

Use of NAC in Alleviation of Hangover Symptoms

Physiological Effects of Nutritional Support in Patients With Parkinson's Disease

Prospective Treatment Efficacy in IPF Using Genotype for Nac Selection (PRECISIONS) Trial

Effect of Intravenous Acetadote on Incidence of Contrast Induced Nephropathy

A 24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome

N-acetylcysteine Effects on Tetrahydrocannabinol

Study of the Safety and Tolerability of AXA1125 and AXA1957 in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)

Acetaminophen in Combination With N-Acetylcysteine (NAC) Versus Placebo in Treating Fever

Overcoming Membrane Transporters to Improve CNS Drug Delivery - Improving Brain Antioxidants After Traumatic Brain Injury

Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1

Evaluation of the Efficacy of Fomepizole in the Treatment of Acetaminophen Overdose

Brain Imaging to Understand the Role of Inflammation in N-Acetyl Cysteine (NAC) Treatment of Bipolar Depression

Pilon Fracture With Intra-articular Injection of N-Acetylcysteine (Pilon NAC)

Treatment of Hemodialysis Catheter-Related Bacteremia

Use of N-Acetylcysteine in the Treatment of Repetitive and Self-Injurious Behaviors in Cornelia de Lange Syndrome

Acetylcysteine, Mannitol, Combination Chemotherapy, and Sodium Thiosulfate in Treating Children With Malignant Brain Tumors

The Role of N-acetyl-l-cysteine (NAC) as an Adjuvant to Opioid Treatment in Patients With Chronic Neuropathic Pain

Marijuana Cue-Reactivity & Seeking Behavior in Regular Cannabis Users

N-acetylcysteine Plus Naltrexone for the Treatment of Alcohol Dependence